UNSPSC 51111664: Aminopterin

This classification denotes a folate antagonist and dihydrofolate reductase inhibitor with the molecular formula C19H20N8O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JYB41CTM2Q, chemically known as folic acid, 4-amino- but generally known as aminopterin, which bears US NIH Compound Identifier 2154. aminopterin most often comes in base, hydrate, n-hydroxysuccinimide ester, and sodium forms. European Medicines Agency schedules Aminopterin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00464MIG.

UNSPSC 51111664 Aminopterin is a Commodity code for a specific pharmaceutical active ingredient; state and local governments procure it primarily through health agencies, Medicaid programs, and public hospital systems as part of prescription drug purchasing and pharmacy benefit management. The code captures aminopterin — a folic acid antagonist used in cancer chemotherapy and certain autoimmune conditions — when acquired through formal procurement channels rather than through routine pharmaceutical wholesale or group purchasing organization channels. State and local procurement under this code reflects the intersection of pharmacy benefit strategy, direct manufacturer sourcing, and cost management initiatives, particularly where jurisdictions seek to bypass traditional pharmacy benefit managers or group purchasing organizations to negotiate net pricing or outcomes-based agreements with pharmaceutical manufacturers.

The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs, including aminopterin and other specialty pharmaceuticals, under a Therapeutic Pharmacy Initiative aimed at improving fulfillment efficiency and cost control. This RFI signals state-level interest in direct contracting models with pharmaceutical manufacturers for self-insured employee and retiree health plans, with vendors expected to demonstrate experience negotiating net pricing models and implementing value-based agreements within the past two years. The RFI is preliminary market intelligence; no formal RFP, budget, award value, or competitive timeline has been announced. Activity under this code remains limited to early-stage procurement planning at the state health-agency level, with no additional recent opportunities posted in other jurisdictions as of the source date.